Filing Flows › Tarsus Pharmaceuticals (TARS) › Q3 2026
Tarsus Pharmaceuticals (TARS) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Tarsus Pharmaceuticals (TARS) reported revenue of $195M for the third quarter 2026 (Q3 2026), +64% from a year earlier and +12% from the quarter before. Operating margin was -340.3%, net loss $668M (343.5% of revenue).
Tarsus Pharmaceuticals, Q3 2026: revenue $195M (+64% year over year), operating margin -340.3%, net loss $668M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $195M | +12% | +64% |
| Operating profit | −$662M | — | — |
| Net earnings | −$668M | — | — |
| Operating cash flow | −$6.0M | -110% | -133% |
What changed
Revenue was $194.6M in Q3 2026, up 64% year over year and up 12% from the previous quarter.
Operating costs exceeded revenue by $662.1M, an operating margin of -340.3%. Total costs grew 543% against revenue growth of 64%. The fastest-growing cost line was Research & development (+171%). The quarter ended with a net loss of $668.3M, wider than the previous quarter's $18.6M loss.
Operating cash flow was −$6.0M. Non-cash charges added back $1.0M of depreciation and amortization and $27.2M of share-based compensation. Working capital and other items added $634.1M. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$7.2M.
Questions
What was Tarsus Pharmaceuticals' revenue in the third quarter 2026?
Tarsus Pharmaceuticals (TARS) reported revenue of $195M for the third quarter 2026 (Q3 2026), +64% from a year earlier and +12% from the quarter before.
Was Tarsus Pharmaceuticals profitable in the third quarter 2026?
Operating loss was $662M (-340.3% of revenue) and net loss $668M.